Logotype for ICU Medical Inc

ICU Medical (ICUI) Q4 2017 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for ICU Medical Inc

Q4 2017 earnings summary

6 Nov, 2026

Executive summary

  • 2017 marked the February acquisition of Hospira Infusion Systems (HIS), transforming the portfolio into a broad infusion-therapy offering spanning consumables, IV solutions, pumps and critical care.

  • Integration advanced through commercial-team consolidation, capacity adjustments and positive FDA inspections at acquired facilities; 2018 was expected to bring execution challenges as Pfizer transition services expired.

Financial highlights

  • FY2017 revenue was $1,292.6M and net income was $68.6M; operating loss was $15.1M, including $78.0M of restructuring and strategic transaction expenses.

  • Diluted EPS was $3.29 vs. $3.66 in 2016; FY2017 included a $70.9M HIS bargain-purchase gain and a $20.8M tax benefit from excess stock-compensation tax benefits.

  • Q4 revenue was $370.1M, gross profit $137.5M, net income $49.7M and diluted EPS $2.33.

  • Operating cash flow was $154.4M; cash, cash equivalents and short-term investments totaled $300.1M at year-end, down $144.9M, primarily due to acquisitions and integration costs.

Outlook and guidance

  • 2018 priorities centered on completing HIS integration and Pfizer carve-out activities; management cautioned that execution demands could reduce predictability.

  • FY2018 capital expenditures were estimated at $80M–$90M for manufacturing equipment, customer-placed infusion products and global IT; actual spending could differ substantially.

  • Management expected available cash and future operating cash flows to fund operations for the next 12 months; focus remained on customer service, innovation and free-cash-flow generation.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from ICU Medical